24 September 2025
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Group")
Change of Accounting Reference Date
Venture Life (AIM: VLG), a leader in product innovation, development and commercialisation within the global consumer healthcare sector, confirms that, further to the announcement on 25 July 2025, it has changed its accounting reference date from 31 December to 31 May to in order to better align with the Group's revised strategy, and with the objective of reducing revenue seasonality and managing specific operating costs more effectively.
Accordingly, the Company's financial calendar will be as follows:
· Unaudited interim accounts for the 12-month period ending 31 December 2025, published by no later than 31 March 2026;
· Audited accounts for the 17-month period ending 31 May 2026, published by no later than 30 November 2026; and
· Unaudited interim accounts for the 6-month period ending 30 November 2026, published by no later than 28 February 2027.
Thereafter, the Company will publish each year its final audited results for the 12-month period ending 31 May as well as its unaudited interim results for the six-month period ending 30 November.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys/George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life ( www.venture-life.com )
Venture Life is an international consumer self-care company focused on commercialising products for the global self-care market. Headquartered in the UK, the Group's product portfolio includes Balance Activ in the area of women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally. In the UK, Ireland and the USA these are supplied direct by the company to retailers, elsewhere they are supplied by the Group's international distribution partners.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.